Sponsors (113)
Official title: To prohibit certain uses of xylazine, and for other purposes.
Introduced February 12, 2025 by James Varni Panetta · Last progress February 12, 2025
The bill strengthens federal authority, definitions, and oversight to disrupt illicit xylazine supply and standardize enforcement, but does so at the cost of increased regulatory/compliance burdens, potential reduced access for legitimate medical uses, and greater risk of criminalization and incarceration without guaranteed new funding for treatment or public‑health responses.
Law enforcement, prosecutors, and courts gain a clear statutory definition, prosecutorial authority, and sentencing guidance for xylazine, enabling more consistent enforcement and improved ability to disrupt illicit supply chains.
Manufacturers, distributors, and registrants get clearer federal scheduling (Schedule III) and expedited FDA/DEA processing, reducing legal ambiguity and easing the transition for legitimate xylazine products.
Tighter controls plus required federal reporting and surveillance can help identify dangerous analogues and limit illicit xylazine availability, supporting earlier public-health interventions that could reduce overdoses and related harms.
Patients who legitimately need xylazine-containing preparations and the healthcare providers who treat them may face reduced access if suppliers exit the market or products become harder to obtain under Schedule III controls.
Expanding statutory definitions (salts, isomers) and prohibiting any quantity risk criminalizing people for trace contamination or residue, potentially widening prosecutions and impacting low-income and vulnerable populations.
Manufacturers, distributors, and healthcare providers will face new compliance costs (DEA registration, recordkeeping, security upgrades) that can burden small businesses and raise costs for health systems and taxpayers.
Based on analysis of 7 sections of legislative text.
Designates xylazine-containing materials as Schedule III, creates definitions and special "ultimate user" rules for animal contexts, delays certain compliance steps, orders sentencing review, and requires DOJ/FDA reports.
Designates xylazine and any preparation containing it as a Schedule III controlled substance under the Controlled Substances Act, creates a statutory definition of xylazine, and adjusts the definition of "ultimate user" for xylazine in contexts involving animals. The bill phases in certain regulatory compliance requirements (registration, recordkeeping, labeling, and security) on transitional schedules, directs the U.S. Sentencing Commission to review federal sentencing guidance for xylazine-related offenses, and requires two reports to Congress on illicit xylazine supply, diversion, and trends.